Key Takeaway: Skye's Project Ascend is a 90-day initiative focused on validating higher-exposure dosing for nimacimab. The project aims to enhance the clinical and translational evidence supporting the role of peripheral CB1 inhibition in treating obesity. This effort represents a significant step forward in addressing obesity through innovative dosing strategies.
Price reaction · baseline $0.8782 (2026-01-02 close) · 6 other SKYE headline(s) in the window, move may be shared
day 0 close
-2.3%
Market Sentiment Analysis
POSITIVE FACTORS
Project Ascend aims to validate higher-exposure dosing.
Focus on strengthening clinical evidence for nimacimab.
Targets peripheral CB1 inhibition in obesity.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity
Full Press Release Details
All
Primers
Perspectives
Progress
Press
Characterizing/Advancing Higher-exposure Dosing
Date published:
January 3, 2026 6:35 pm PST
Share
Project Ascend is Skye’s 90-day roadmap to validate higher-exposure dosing for nimacimab and strengthen the clinical and translational evidence behind peripheral CB1 inhibition in obesity.
Frequently Asked Questions
What is Project Ascend?
Project Ascend is Skye's 90-day initiative to validate higher-exposure dosing for nimacimab.
What does higher-exposure dosing aim to achieve?
It aims to strengthen clinical evidence for peripheral CB1 inhibition in obesity.
When was the article published?
The article was published on January 3, 2026.
What is nimacimab used for?
Nimacimab is being investigated for its role in treating obesity.